MSH6 alterations were present in 34 patients overall, most commonly in the STS cohort (n=21), including six patients with leiomyosarcoma, five patients with undifferentiated pleomorphic sarcoma, five patients with sarcoma NOS, two patients with pleomorphic rhabdomyosarcoma, one patient angiosarcoma, one patient with dedifferentiated liposarcoma, and one with follicular dendritic cell sarcoma. Here, MSH6 is linked to pleomorphic rhabdomyosarcoma.